Tango Therapeutics, Inc. filed a Form 8-K with the SEC on August 11, 2026, disclosing results of operations and financial condition for the quarter ended June 30, 2026, via an attached press release.

Key Highlights

  • Reporting period: Quarter ended June 30, 2026.
  • Filing date: August 11, 2026, the same date as the earliest event reported.
  • Press release: A copy is furnished as Exhibit 99.1 to the filing.
  • Furnished, not filed: The press release and Exhibit 99.1 are furnished under Item 2.02 and are "not deemed filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signatory: Matthew Gall, Chief Financial Officer, signed the filing on behalf of the registrant.

Tango Therapeutics Files 8-K Covering Q2 2026 Operating Results

Tango Therapeutics, Inc. (NASDAQ:TNGX) filed a current report on August 11, 2026 under Item 2.02 of Form 8-K, which covers results of operations and financial condition. According to the filing, the company issued a press release on that same date relating to its financial results for the quarter ended June 30, 2026. The full content of that press release is contained in Exhibit 99.1, which was attached to the filing.

The filing explicitly states that the press release and the information set forth therein, including Exhibit 99.1, "shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended." The filing further notes that the exhibit "shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein." These characterizations are the company's own as stated in the disclosure.

Tango Therapeutics is incorporated in Delaware and lists its principal executive offices at 201 Brookline Ave., Suite 901, Boston, MA 02215. The registrant's common stock, par value $0.001 per share, is registered on The Nasdaq Global Market under the trading symbol TNGX. The filing was signed by Chief Financial Officer Matthew Gall on August 11, 2026.

What Was Disclosed

Tango Therapeutics furnished an 8-K on August 11, 2026 to report its financial results for the quarter ended June 30, 2026. The press release containing those results is attached as Exhibit 99.1 and is furnished, not filed, under SEC rules.